Neuralstem asks FDA to clear stem cell study
Neuralstem has asked the Food and Drug Administration to approve an early-stage safety study on a potential spinal cord injury treatment, the company said Wednesday.
The treatment was developed using adult stem-cell technology, specifically with stem cells taken from the spinal cord.
Shares of Neuralstem Inc. rose 20 cents, or 11.1 percent, to $2 in afternoon trading. The stock has traded between $1.04 and $3.49 over the last 52 weeks.